FDA approves Novartis Piqray® for patients with PIK3CA mutation in HR+/HER2 MBC
Novartis announced the FDA has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative, PIK3CA-mutated, advanced or metastatic breast cancer. May 24, 2019